Rheumatology billing
runs on drug economics.
The clinical work is rheumatology. The billing is drug economics: who bought the biologic, what the dose weighs out to in units, which of four near-identical products actually went in, and whether the plan authorized the drug, the site and the administration or only one of the three.
Whether you bought the drug decides everything downstream
Buy-and-bill or white bag is not a billing detail. It is the first fork in the claim. Under a bagging mandate the drug is not a line you own, only the administration is, and a practice that keeps billing for the drug accumulates denials on top of inventory it has already paid for. The mandate is per payer, sometimes per plan, and it moves. Confirming it at intake costs a phone call.
- Acquisition model confirmed per payer and per plan before the drug is ordered
- Administration billed correctly on the encounters where the drug is not yours to bill
- Brown bagging and clear bagging handled as the distinct arrangements payers treat them as
- Buy-and-bill exposure raised before the practice has money sitting in inventory
The units move when the patient does
A weight-dosed biologic does not produce the same claim twice. The order is in milligrams per kilogram, the claim is in fixed increments of drug, and a patient who gained eight pounds since the last cycle is a different unit count. Carrying last cycle forward is the common version of this and it is invisible until an audit. Wastage from a vial that did not divide evenly is the other half, and it gets reported rather than absorbed.
- Dose converted to billable units at every visit, never carried forward from the last
- Administered units reconciled against billed units on a claim sample during the assessment
- Single-dose vial wastage documented and reported with the modifier the payer expects
Interchangeable in the chair, not on the claim
Each biosimilar carries its own code, and the purchase record is what proves which product went in. Bill the originator for a biosimilar and it denies. The harder problem is that payer preference between them moves, sometimes inside a plan year, so a claim that paid clean in March denies in July with nothing changed at your end. That is a policy problem wearing a denial costume, and working it one claim at a time never closes it.
- Code billed matched to the product actually administered, checked against purchasing
- Preferred product tracked per payer, because it is not consistent between them
- Formulary shifts caught at policy level rather than one denial at a time
One drug, three authorizations
Plans increasingly authorize the drug, the site of care and the administration as separate decisions. Any one of them missing takes the whole encounter with it. Step therapy sits underneath all of that, and the clinical history almost always supports it. What is usually missing is the history in the shape the payer asked for, which is a different problem and a cheaper one to fix before submission than after.
- Drug, site of care and administration authorizations tracked as three, not as one
- Step-therapy documentation assembled to the payer policy rather than to a template
- Authorization re-checked when the regimen, the interval or the site changes
- Peer-to-peer review pursued when a payer refuses, rather than written off
The infusion codes deny more often than the drug does
Administration is coded from chair time and from a hierarchy: what was initial, what ran sequentially, what ran concurrently. Practices lose at both ends. Undercoding the hierarchy leaves hours in the chair unbilled. Overcoding it, or reporting an office visit alongside an injection without support for doing so, produces the same-day bundling denial that shows up on most rheumatology denial reports.
- Hierarchy coded from documented chair time and sequence, not from the last claim
- Same-day evaluation and management examined for whether it is separately reportable
- Drug and administration lines reconciled against each other before submission
This is what we watch for. How the engagement runs is a separate question.
Before any of it applies to your practice we read your aged A/R and the last quarter of remittance advice, and you get the findings in writing including what we think is not worth chasing. You keep your practice management system, your payer contracts and your NPI throughout.